Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio.
According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA approval.
Get the full story at our sister site, Drug Delivery Business News.
The post Cordis inks exclusive distribution deal for Medinol’s coronary stent portfolio in US appeared first on MassDevice.